AstraZeneca’s first-in-class pan-AKT inhibitor Truqap was unable to improve overall survival (OS) in a phase 3 trial in triple-negative breast cancer (TNBC), denting the prospects of the new drug.

Creation Healthcare analysed over 80,000 posts on X (formerly Twitter) referencing prostate cancer between January 2024 and January 2025 - authored by more than 17,000 individual HCPs.

Check out our AZN stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.

Find the latest AstraZeneca PLC (AZN.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.